CARGO Therapeutics, Inc. (CRGX)
- Previous Close
18.28 - Open
18.46 - Bid 18.54 x 100
- Ask 18.72 x 100
- Day's Range
18.26 - 18.86 - 52 Week Range
13.14 - 33.92 - Volume
85,619 - Avg. Volume
311,792 - Market Cap (intraday)
735.405M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
32.00
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
cargo-tx.comRecent News: CRGX
Performance Overview: CRGX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRGX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRGX
Valuation Measures
Market Cap
735.41M
Enterprise Value
358.22M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.81
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-3.86
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.09%
Return on Equity (ttm)
-53.03%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-98.15M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
405.73M
Total Debt/Equity (mrq)
7.04%
Levered Free Cash Flow (ttm)
-68.1M